MX2007004549A - Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico. - Google Patents

Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico.

Info

Publication number
MX2007004549A
MX2007004549A MX2007004549A MX2007004549A MX2007004549A MX 2007004549 A MX2007004549 A MX 2007004549A MX 2007004549 A MX2007004549 A MX 2007004549A MX 2007004549 A MX2007004549 A MX 2007004549A MX 2007004549 A MX2007004549 A MX 2007004549A
Authority
MX
Mexico
Prior art keywords
kinase inhibitor
bortezomib
growth factor
factor receptor
epidermal growth
Prior art date
Application number
MX2007004549A
Other languages
English (en)
Inventor
Bilal Piperdi
Original Assignee
Bilal Piperdi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bilal Piperdi filed Critical Bilal Piperdi
Publication of MX2007004549A publication Critical patent/MX2007004549A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invencion proporciona un metodo para fabricar un medicamento destinado para tratar tumores o metastasis tumorales en un paciente, caracterizado porque se utiliza una cantidad terapeuticamente efectiva de un inhibidor de la cinasa de EGFR y bortezomib, con o sin agentes adicionales o tratamientos, tales como otros farmacos anticancerosos o terapia con radiacion. La invencion tambien abarca una composicion farmaceutica que esta comprendida de una combinacion del inhibidor de la cinasa de EGFR y el bortezomib, en combinacion con un portador farmaceuticamente aceptable. Un ejemplo preferido de un inhibidor de la cinasa de EGFR que puede ser utilizado en la practica de esta invencion, es el compuesto clorhidrato de erlotinib (tambien conocido como TarcevaMR).
MX2007004549A 2004-10-18 2005-10-18 Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico. MX2007004549A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61984404P 2004-10-18 2004-10-18
PCT/US2005/037324 WO2006110175A2 (en) 2004-10-18 2005-10-18 Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2007004549A true MX2007004549A (es) 2007-07-11

Family

ID=36922148

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004549A MX2007004549A (es) 2004-10-18 2005-10-18 Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico.

Country Status (11)

Country Link
US (1) US20060084691A1 (es)
EP (1) EP1804809A2 (es)
JP (1) JP2008516983A (es)
KR (1) KR20070083719A (es)
CN (1) CN101043892A (es)
AU (1) AU2005330507A1 (es)
BR (1) BRPI0517104A (es)
CA (1) CA2583520A1 (es)
IL (1) IL182584A0 (es)
MX (1) MX2007004549A (es)
WO (1) WO2006110175A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1651612T3 (pl) 2003-07-22 2012-09-28 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
MXPA06013999A (es) * 2004-06-03 2007-02-08 Hoffmann La Roche Tratamiento con irinotecan (cpt-11) y un inhibidor de la quinasa del receptor del factor de crecimiento epidermal (egfr).
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) * 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
WO2007146226A2 (en) * 2006-06-09 2007-12-21 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
JP5926487B2 (ja) 2007-04-13 2016-05-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ＥｒｂＢ療法に耐性である癌を治療するための方法
WO2010022277A2 (en) * 2008-08-20 2010-02-25 O'connor Owen A Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers
EA201170527A1 (ru) * 2008-10-01 2011-10-31 Др. Редди'С Лабораторис Лтд. Фармацевтические композиции, включающие соединения бороновой кислоты
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
PT2355828T (pt) * 2008-11-13 2018-07-02 Gilead Calistoga Llc Terapias para malignidades hematológicas
US9061037B2 (en) * 2010-03-18 2015-06-23 Innopharma, Inc. Stable bortezomib formulations
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
EP2598114A1 (en) * 2010-07-28 2013-06-05 Fondazione Irccs "Istituto Nazionale del Tumori" Therapeutic agent, composition including said agent, implantable device and process for the treatment of cervical cancer and/or for the prevention of the formation of neoplasms in correspondence of the cervix in a human female genital system.
KR20140033384A (ko) * 2011-05-16 2014-03-18 울리커 누베르 신규한 암 치료제 및 방법
KR101695237B1 (ko) * 2013-10-11 2017-01-12 이화여자대학교 산학협력단 보르테조밉을 유효성분으로 함유하는 간독성 질환의 예방 및 치료용 조성물
EP3291819A4 (en) * 2015-05-05 2018-11-21 The Regents of the University of California Improved drug combinations for drug-resistant and drug-sensitive multiple myeloma
WO2019169389A1 (en) * 2018-03-02 2019-09-06 Epicentrx, Inc. Methods and compositions for treating cancer and sensitizing tumor cells to kinase inhibitors
US20210393632A1 (en) * 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
TW202237143A (zh) 2020-12-10 2022-10-01 南韓商Ｌｇ化學股份有限公司 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物
KR20220118247A (ko) 2021-02-18 2022-08-25 김성운 커트용 헤어빗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010524A (pt) * 1999-05-14 2002-05-28 Imclone Systems Inc Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
WO2004010937A2 (en) * 2002-07-26 2004-02-05 Advanced Research & Technology Institute At Indiana University Method of treating cancer

Also Published As

Publication number Publication date
CA2583520A1 (en) 2006-10-19
US20060084691A1 (en) 2006-04-20
AU2005330507A1 (en) 2006-10-19
WO2006110175A2 (en) 2006-10-19
EP1804809A2 (en) 2007-07-11
CN101043892A (zh) 2007-09-26
WO2006110175A3 (en) 2007-03-08
IL182584A0 (en) 2008-04-13
KR20070083719A (ko) 2007-08-24
WO2006110175A9 (en) 2006-11-23
BRPI0517104A (pt) 2008-09-30
JP2008516983A (ja) 2008-05-22

Similar Documents

Publication Publication Date Title
MX2007004549A (es) Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
WO2006110176A3 (en) Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
TW200603804A (en) Treatment with irinotecan (cpt-11) and an EGFR-inhibitor
WO2007106503A3 (en) Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
NO20066056L (no) Behandling med Gemcitabin og en EGFR-inhibitor
NO20066054L (no) behandling med cisplatin og en EGFR-inhibitor
MX339142B (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
WO2009008992A3 (en) Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
HK1071310A1 (en) Combination therapy for the treatment of cancer
TW200608959A (en) Treatment with oxaliplatin and an egfr-inhibitor
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
AU2014248377B2 (en) Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
MX2007006927A (es) Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer.
WO2009073139A3 (en) Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit
CA2514227A1 (en) Combination therapy of zd6474 with 5-fu or/and cpt-11
Vokes Current treatments and promising investigations in a multidisciplinary setting
EA200901145A1 (ru) Применение рибофлавина в лечении гипертензии
MXPA04009012A (es) Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer.
US20160367553A1 (en) Methods and Compositions for Treating Cancers having Acquired Resitance to prior Chemotherapeutic and Targeted Drugs Using Carboxyamidotriazole Orotate
TNSN08512A1 (en) Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists
Vokes Symposium article Current treatments and promising investigations in a multidisciplinary setting
MXPA05008879A (es) Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral.
TH84265A (th) การรักษาด้วยอิริโนทีแคน (cpt-11) และสารยับยั้ง egfr

Legal Events

Date Code Title Description
FA Abandonment or withdrawal